MedTrace Logo

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2015-12-02

No results posted yet for this study

Summary

Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and during treatment.

Conditions

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Richard M. Bergenstal, MD · International Diabetes Center at Park Nicollet

  • Roger S. Mazze, PhD · International Diabetes Center at Park Nicollet

  • Robert M. Cuddihy, MD · International Diabetes Center at Park Nicollet

  • Elinor (Ellie) S. Strock, APRN, BS,CDE · International Diabetes Center at Park Nicollet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00806520 on ClinicalTrials.gov